Why the study?
Does the discontinuation of RAS inhibitors affect the long-term rate of decrease in eGFR in patients with advanced and progressive chronic kidney disease?
Does the discontinuation of RAS inhibitors affect the long-term rate of decrease in eGFR in patients with advanced and progressive chronic kidney disease?
Discontinuing RAS inhibitors in advanced and progressive chronic kidney disease does not significantly alter the long-term rate of eGFR decline.
Answers are grounded in this paper and cite their sources.
Discontinuation of RAS inhibitors does not accelerate eGFR decline in advanced CKD; extends evidence for individualized use.
Among patients with advanced and progressive chronic kidney disease, the discontinuation of RAS inhibitors was not associated with a significant between-group difference in the long-term rate of decrease in the eGFR. (Funded by the National Institute for Health Research and the Medical Research Council; STOP ACEi EudraCT number, 2013-003798-82; ISRCTN number, 62869767.).
No takes yet. Share an insight, caveat, or question.
Bhandari et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: